Skip to main content

Veracyte, Inc. (VCYT) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Diagnostics & Research

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $32.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 8.00; Negative price momentum; Below long-term trend.

Veracyte is a global cancer diagnostics company offering molecular diagnostic tests including Decipher Prostate, Afirma (thyroid), Prosigna (breast), and Decipher Bladder. U.S. tests are performed as LDTs in CLIA-certified labs; internationally, IVD tests are distributed to... Read more

$32.50+24.6% A.UpsideScore 5.3/10#12 of 25 Diagnostics & Research
Stop $30.23Target $40.49(analyst − 13%)A.R:R 2.8:1
Analyst target$46.55+43.2%11 analysts
$40.49our TP
$32.50price
$46.55mean
$53

Sell if holding. Engine safety override at $32.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 8.00; Negative price momentum; Below long-term trend. Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: aggressive.

Val6.3Qual6.1Grw7.1Mom2.3Sent7.2Ins3.3Peer3.8Tech4.9Risk2.35.3OVERALL

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: Decipher Prostate and Afirma
Concentration risk — Customer: Medicare and UnitedHealthcare Group
Risk below floor (2.3 < 3.0)

Key Metrics

P/E (TTM)38.8
P/E (Fwd)18.0
Mkt Cap$2.5B
EV/EBITDA25.5
Profit Mgn12.8%
ROE5.3%
Rev Growth18.5%
Beta1.96
DividendNone
Rating analysts19

Quality Signals

Piotroski F8/9

Options Flow

P/C8.00bearish
IV127%elevated
Max Pain$18-46.2% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductDecipher Prostate and Afirma
    10-K Item 1A: 'Our financial results currently depend mainly on sales of our Decipher Prostate and Afirma laboratory developed tests (LDTs)'
  • HIGHCustomerMedicare and UnitedHealthcare Group
    10-K Item 1A: 'We depend on a few payers for a significant portion of our revenue ... such as Medicare and UnitedHealthcare Group'

Material Events(8-K, last 90d)

  • 2026-03-16Item 5.02LOW
    Dr. Kevin Haas, 40, appointed as Chief Development and Technology Officer effective March 24, 2026. Previously CTO at Myriad Genetics. New role appointment; no prior holder departed.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.0
Obv
1.0
Ma Position
2.2
Macd
3.8
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.5%/30d) — pullback in uptrend, not confirmed weakness

Risk profile below the gate floor. Component breakdown shows what dragged the score down.static

Put Call
0.0
Implied Vol
0.0
Volatility
1.4
Debt Equity
2.0
Max Pain Risk
3.0
Days To Cover
3.3
Beta
3.5
Short Interest
5.2
Elevated put/call: 8.00High IV: 127%Above max pain $18Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
2.7
Quality Rank
4.9
Growth Rank
7.6
GatesMomentum 2.3<4.5EARNINGS PROXIMITY 5d<=7dA.R:R 2.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
56 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $30.56Resistance $35.19

Price Targets

$30
$40
A.Upside+24.6%
A.R:R2.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Risk below floor (2.3 < 3.0)
! Momentum score 2.3/10 — below 4.5 minimum
! EARNINGS_PROXIMITY:5d<=7d

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is VCYT stock a buy right now?

Sell if holding. Engine safety override at $32.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 8.00; Negative price momentum; Below long-term trend. Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $30.23. Score 5.3/10, moderate confidence.

What is the VCYT stock price target?

Take-profit target: $40.49 (+24.6% upside). Prior stop was $30.23. Stop-loss: $30.23.

What are the risks of investing in VCYT?

Concentration risk — Product: Decipher Prostate and Afirma; Concentration risk — Customer: Medicare and UnitedHealthcare Group; Risk below floor (2.3 < 3.0).

Is VCYT overvalued or undervalued?

Veracyte, Inc. trades at a P/E of 38.8 (forward 18.0). TrendMatrix value score: 6.3/10. Verdict: Sell.

What do analysts say about VCYT?

19 analysts cover VCYT with a consensus score of 4.1/5. Average price target: $47.

What does Veracyte, Inc. do?Veracyte is a global cancer diagnostics company offering molecular diagnostic tests including Decipher Prostate, Afirma...

Veracyte is a global cancer diagnostics company offering molecular diagnostic tests including Decipher Prostate, Afirma (thyroid), Prosigna (breast), and Decipher Bladder. U.S. tests are performed as LDTs in CLIA-certified labs; internationally, IVD tests are distributed to local labs. Revenue depends primarily on Decipher Prostate and Afirma reimbursement.

Related stocks: WGS (GeneDx Holdings Corp.) · NEO (NeoGenomics, Inc.) · SHC (Sotera Health Company) · GH (Guardant Health, Inc.) · BLLN (BillionToOne, Inc.)